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Abstract
Background: Estrogens and androgens have extensive effects on the immune system, for example
they suppress both T and B lymphopoiesis in thymus and bone marrow. Submandibular glands are
sexually dimorphic in rodents, resulting in larger granular convoluted tubules in males compared
to females. The aim of the present experiments was to investigate the estrogenic and androgenic
effects of 4-estren-3α,17β-diol (estren) on thymus, bone marrow and submandibular glands, and
compare the effects to those of 17β-estradiol (E2) and 5α-dihydrotestosterone (DHT),
respectively. Estrogen receptors (ERs) were blocked by treatment of mice with the ER-antagonist
ICI 182,780; also, knock-out mice lacking one or both ERs were used.
Results: As expected, the presence of functional ERs was mandatory for all the effects of E2.
Similar to DHT-treatment, estren-treatment resulted in decreased thymus weight, as well as
decreased frequency of bone marrow B cells. Treatment with estren or DHT also resulted in a shift
in submandibular glands towards an androgen phenotype. All the effects of estren and DHT were
independent of ERs.
Conclusion: Our study is the first to show that estren has similar effects as the androgen DHT
on lymphopoiesis in thymus and bone marrow, and on submandibular glands, and that these effects
are independent of estrogen receptors. This supports the hypothesis of estren being able to signal
through the androgen receptor.
Background
The effects of estrogens and androgens on the immune
system in mice have been extensively studied. For exam-
ple, B and T lymphopoiesis in bone marrow and thymus
is suppressed by treatment with both estrogens [1-6] and
androgens [7-9].
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rodents. The secretory activity of these glands is mainly
localized to the acinar cells and the granular convoluted
tubular (GCT) cells. The GCT cells are under hormonal
control involving androgens, resulting in larger GCT in
males compared to females [10-12].
Signals from estrogens and androgens are transmitted into
the target cells by the two known estrogen receptors (ERs),
ERα and ERβ [13,14], or by the androgen receptor (AR),
respectively.
Postmenopausal hormone replacement therapy (HRT)
has beneficial effects on the skeleton, but is associated
with well-known side effects. This has lead to an increased
focus on finding synthetic estrogen-like substances that
only reproduce the beneficial effects of estrogen. 4-estren-
3α,17β-diol (estren) is a synthetic compound with struc-
tural similarities to E2 that has been suggested to signal
through both ERs and the AR [15-17].
The aim of the present experiments was to investigate the
estrogenic and androgenic effects of estren on lymphopoi-
esis in thymus and bone marrow, and on SMG. We show
here that estren has similar effects on these organs as the
androgen DHT, and that the effects are independent of
ERs, supporting the previous studies showing that estren
is able to signal through the AR[15,16].
Results
Experiment 1: Estren does not affect thymus, bone marrow 
B cells or submandibular glands through ERs
We wanted to investigate the estrogenic effects of estren
on lymphopoiesis and submandibular glands (SMG) in
female mice. In order to do this, 3-month-old female
C57/B16 mice were ovariectomized and treated during
18–21 days with daily subcutaneous (s.c.) injections of
the estrogen receptor antagonist ICI 182,780 (200 µg/
day) or vehicle Miglyol 812. Simultaneously, both the
vehicle and the ICI groups were given daily s.c. injections
of E2 (0.7 µg/day), estren (75 µg/day) or control Miglyol
812 oil.
The inhibitory effects of E2 on thymus weight (fig. 1) and
frequency of CD19+ cells in bone marrow (fig. 2) in vehi-
cle-exposed mice were blocked by the ER-antagonist ICI
182,780. In contrast, treatment with estren resulted in
lower thymus weight (fig. 1) and lower frequency of
CD19+ cells in bone marrow (fig. 2), in both vehicle and
ICI exposed mice.
The granular convoluted tubules in SMG are sexually
dimorphic in rodents, being larger in males than in
females. In eosin-hematoxylin stained tissue sections of
SMG, the degree of the androgen phenotype was scored
from 0 to 3. 0 represents no androgen phenotype and 3 is
the highest score for androgen phenotype. Representative
pictures for the different scoring points are presented in
fig. 3. Treatment with E2 did not affect the SMG weight
(fig. 4a) or score for androgen phenotype (fig. 4b) in
either vehicle or ICI mice. Furthermore, both the SMG
weight (fig. 4a) and the SMG score for androgen pheno-
type (fig. 4b) was increased by estren in both vehicle and
ICI mice.
Taken together, results from this experiment indicate that
estren affects lymphopoiesis and SMG through ER-inde-
pendent pathways.
Experiment 2: Estren and DHT affect the frequency of 
B220+ cells in bone marrow, and submandibular gland 
phenotypes, through ER independent pathways
Since previous studies have shown that estren has the abil-
ity to signal through both ERs and AR[15,16], we wanted
to investigate the estrogen-, and androgen-like effects of
estren in female ER knock-out mice. In order to do this,
11-month-old female WT and DERKO (ERα-/-, ERβ-/-)
mice were ovariectomized and given daily s.c. injections
of E2 (0.7 µg/day), DHT (120 µg/day) or estren (75 µg/
day) during four weeks. Control mice received olive oil.
As expected, the E2-mediated reduction of the frequency
of B220+ cells in bone marrow of WT mice was lacking in
DERKO mice (fig. 5). E2-treatment did not dramatically
affect the weight (data not shown) or the androgen phe-
notype of SMG in either WT or DERKO mice (fig. 6).
We have previously shown that estren-treatment results in
decreased thymus cellularity in both WT and DERKO
mice indicating an effect through ER independent path-
ways[17]. We now also show that treatment with DHT or
estren resulted in lower frequency of B220+ cells in bone
marrow of both WT and DERKO mice (fig. 5). Further-
more, fig. 6 shows that the SMG score for androgen phe-
notype was high for both DHT- and estren-treated mice,
of both WT and DERKO genotype, when compared to
control mice. Interestingly, the SMG weight was signifi-
cantly increased in DHT-treated mice compared to con-
trols, but not in estren- or E2-treated mice (data not
shown).
Altogether, results from this experiment show again that
estren affects B cells in bone marrow, and the phenotype
of SMG, through ER-independent pathways in a manner
similar to DHT-treatment. This indicates estren-signalling
through the AR.Page 2 of 12
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cellularity and an androgen phenotype of submandibular 
glands
In order to study how E2- and DHT-treatment affected
male ER knock-out mice, 9-month-old male WT and
DERKO mice were orchidectomized and treated for 4
weeks with E2 (0.05 µg/day) or DHT (45 µg/day), admin-
istered by s.c. silastic implants in the cervical region[18].
Vehicle animals received empty implants.
The E2-mediated reduction of thymus cellularity seen in
WT mice could not be detected in DERKO mice (fig. 7).
However, E2-treatment did not affect the weight (data not
shown) or androgen phenotype of SMG in either WT or
DERKO mice (fig. 8).
Treatment with DHT resulted in dramatically reduced thy-
mus cellularity independent of ER genotype (fig. 7). Fur-
thermore, fig. 8 shows that the SMG score for androgen
phenotype was increased in DHT-treated mice of both WT
and DERKO genotype. The SMG weight was also signifi-
cantly increased in DHT-treated mice of both ER geno-
types compared to control- and E2-treated mice (data not
shown).
In conclusion, these data show that also in male mice
DHT affects both thymus cellularity, and SMG weight and
phenotype, independently of ERs.
Experiment 4: Aged ERKO mice have increased salivary 
gland weight that displays an androgen phenotype
Finally, untreated 18-month-old WT, ERKO, BERKO, and
DERKO mice were investigated. We found that aged non-
ovariectomized female mice lacking ERα (ERKO) dis-
played an increased SMG weight, size and an androgen
histological phenotype (9a-c). We have previously shown
Estren reduces thymus weight independently of estrogen receptorsFigure 1
Estren reduces thymus weight independently of estrogen receptors. Ovariectomized 3-month-old female C57/B16 
mice were treated for 18–21 days with daily s.c. injections of the estrogen receptor antagonist ICI 182,780 (200 µg/day) or 
vehicle Miglyol 812. Simultaneously, both the vehicle and the ICI groups were given daily s.c injections of either E2 (0.7 µg/day), 
estren (75 µg/day) or control Miglyol 812 oil. ICI 182,780 blocked the inhibitory effect of E2 on thymus weight. Treatment with 
estren resulted in lower thymus weight in both vehicle and ICI mice. One-way ANOVA followed by Fisher's test was used to 
compare data from mice in different treatment groups. Results are presented as mean ± standard deviation. * P < 0.05, *** P < 
0.001.Page 3 of 12
(page number not for citation purposes)
BMC Immunology 2005, 6:16 http://www.biomedcentral.com/1471-2172/6/16Estren reduces the frequency of CD19+ B cells in bone marrow independently of estrogen receptorsFigure 2
Estren reduces the frequency of CD19+ B cells in bone marrow independently of estrogen receptors. Ovariect-
omized 3-month-old female C57/B16 mice were treated for 18–21 days with daily s.c. injections of the estrogen receptor 
antagonist ICI 182,780 (200 µg/day) or vehicle Miglyol 812. Simultaneously, both the vehicle and the ICI groups were given daily 
s.c injections of either E2 (0.7 µg/day), estren (75 µg/day) or control Miglyol 812 oil. ICI 182,780 blocked the inhibitory effect 
of E2 on the frequency of CD19+ B cells in bone marrow. Treatment with estren resulted in lower frequency of CD19+ B cells 
in bone marrow in both vehicle and ICI mice. One-way ANOVA followed by Fisher's test was used to compare data from mice 
in different treatment groups. Results are presented as mean ± standard deviation. * P < 0.05, *** P < 0.001.
Representative photos of the androgen phenotype scoring pointsFigure 3
Representative photos of the androgen phenotype scoring points. The picture shows representative photos of the 
scorings (0–3) used to evaluate the degree of androgen phenotype in eosin-hematoxylin stained SMG sections. The degree of 
the androgen phenotype in the SMG sections were scored from 0 = no androgen phenotype, to 3 = maximal androgen 
phenotype.Page 4 of 12
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sterone compared to WT mice[19]. Therefore, these results
indicate that high levels of testosterone in ERKO mice are
responsible for the increased SMG weight, size and andro-
gen phenotype in aged female ERKO mice.
Discussion
Postmenopausal hormone replacement therapy (HRT)
has beneficial effects on the skeleton but is associated with
well-known side effects. This has lead to an increased
focus on finding synthetic estrogen-like substances that
only reproduce the beneficial effects of estrogen. Estren is
a synthetic compound that we have recently shown to
have ER-dependent suppressive effects on inflammation,
but ER-independent inhibitory effects on T lymphopoie-
sis [17]. The aim of the present experiments was to inves-
tigate the estrogenic and androgenic effects of estren on
lymphopoiesis in thymus and bone marrow, and on
SMG. Our study is the first to show that estren has similar
effects on these organs as the androgen DHT, supporting
the hypothesis that estren is able to signal through the AR.
In genomic signalling pathways, estrogen binds to intrac-
ellular or – possibly - membrane bound ERs, ultimately
activating transcriptional activity in the target cell. How-
ever, reports have shown that a variety of cell types
respond rapidly, within seconds or minutes, making the
genomic signalling pathway unlikely and suggesting
instead non-genomic signalling pathways. In previously
published papers, Kousteni et al [20-22] proposed that sex
steroids affect reproductive tissues by classical genomic
signalling, while the bone sparing effect of sex steroids is
mediated through a non-genomic pathway. It was sug-
gested that ERα, ERβ or AR can activate the non-genomic
signalling pathway irrespective of whether the ligand is an
estrogen or an androgen. They also showed that treatment
with estren increases bone mass in ovariectomized mice
without affecting reproductive organs, suggesting that
estren is a "mechanism specific" compound that only
reproduces the non-genomic signalling of estrogen, and
thus can affect target cells also through the AR.
In constrast to the findings by Kousteni et al, we have pre-
viously shown that estren has the capacity to affect both
bone and reproductive organs through classical genomic
signalling via ERs[23].
Furthermore, Centrella et al[15] found that estren acti-
vates osteoblasts in a genomic and AR-dependent way.
Interestingly, they also showed that estren can be metab-
olized into 19-nortestosterone by action of 3α-hydroxys-
teroid dehydrogenase, and that 19-nortestosterone binds
to AR with an affinity that was approximately 40% of that
of DHT.
Estren induces increased submandibular gland weight and androgen phenotype independently of estrogen receptorsFigure 4
Estren induces increased submandibular gland weight and androgen phenotype independently of estrogen 
receptors. Ovariectomized 3-month-old female C57/B16 mice were treated for 18–21 days with daily s.c. injections of the 
estrogen receptor antagonist ICI 182,780 (200 µg/day) or vehicle Miglyol 812. Simultaneously, both the vehicle and the ICI 
groups were given daily s.c injections of either E2 (0.7 µg/day), estren (75 µg/day) or control Miglyol 812 oil. Treatment with 
E2 did not affect the SMG weight (A) or score for androgen phenotype (B) in either vehicle or ICI mice. Estren-treatment 
resulted in increased SMG weight (A) and SMG score for androgen phenotype (B) in both vehicle and ICI mice. One-way 
ANOVA followed by Fisher's test was used to compare data from mice in different treatment groups (A). Results are pre-
sented as mean ± standard deviation. **P < 0.01, *** P < 0.001.Page 5 of 12
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estren to be a potent AR ligand with the ability to translo-
cate AR into the nucleus, and possess full AR agonist activ-
ity. In conclusion, results from these studies show that the
ER-independent effects of estren may be mediated
through the AR.
We have recently demonstrated that estren affects periph-
eral immune functions through ERs, while the inhibitory
effects on T lymphopoiesis is ER-independent[17]. Since
also AR stimulation is known to down-regulate both T
and B cell development [7-9], the non ER-mediated effects
of estren on thymus may results from activation of AR.
In the present report we have studied the estrogenic and
androgenic effects of estren on thymus, B cells in bone
marrow and on SMG. We show here that blocking of ERs
with ICI 182,780 does bot affect the estren-induced inhi-
bition of thymus weight (fig. 1). We have previously
shown that exposure to estren results in decreased thymus
cellularity independently of ERs[17]. In this study we also
show that treatment with DHT results in decreased thy-
mus cellularity in both WT and DERKO mice (fig. 7).
Similarly, we show here that blocking of ERs with ICI
182,780 does not affect the frequency of CD19+ B cells in
bone marrow (fig. 2), and independently of ERs, both
DHT- and estren-treatment results in lower frequency of
B220+ B cells in bone marrow (fig. 5).
SMG are sexually dimorphic in rodents, resulting in larger
granular convoluted tubules in males compared to
females [10-12]. In this study, the SMG sections were
scored according to their androgen phenotype (fig. 3) and
DHT and estren reduce the frequency of B220+ cells bone marrow independently of estrogen receptorsFigure 5
DHT and estren reduce the frequency of B220+ cells bone marrow independently of estrogen receptors. Ova-
riectomized 11-month-old female WT and DERKO mice were given daily s.c injections of E2 (0.7 µg/day), DHT (120 µg/day) 
or estren (75 µg/day) during four weeks. Control mice received olive oil. As expected, the E2 mediated reduction of B220+ 
cells in bone marrow of WT mice was lacking in DERKO mice. Treatment with DHT or estren resulted in a lower frequency 
of B220+ cells in bone marrow of both WT and DERKO mice. One-way ANOVA followed by Fisher's test was used to com-
pare data from mice in different treatment groups. Results are presented as mean ± standard deviation. * P < 0.05, * *P < 0.01, 
*** P < 0.001.Page 6 of 12
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does not affect the increased score of androgen phenotype
(fig. 4b) or increased SMG weight (fig. 4a) seen after expo-
sure to estren. We also show that treatment with estren or
DHT of both ovariectomized female and orchidectomized
male mice, results in an androgen phenotype (fig. 6 and
8) in both WT and DERKO mice. Interestingly in experi-
ment 2, estren-treated WT and DERKO mice did not dis-
play increased SMG weight in correlation to their
increased androgen phenotype. The reason for this is not
clear, but one possible explanation could be that a longer
treatment period is necessary to induce the increase in
SMG weight of aged female mice.
In experiment 4, we demonstrate that aged untreated
female mice lacking ERα have an androgen SMG pheno-
type (fig. 9a–c). This is very likely due to the increased tes-
tosterone levels found in these mice [19].
Conclusion
We have recently demonstrated that estren affects periph-
eral immune functions through ERs, while the inhibitory
effects on T lymphopoiesis is ER-independent[17]. Since
AR-stimulation is known to down-regulate both T and B
cell development [7-9], and it has been shown that estren
has the ability to signal also through the AR[15,16], the
non ER-mediated effects of estren may result from activa-
tion of AR. In this study we show that estren has similar
non ER-mediated effects on lymphopoiesis as the andro-
gen DHT in both thymus and bone marrow, and on the
phenotype of SMG. This strongly supports the hypothesis
of estren having the capacity to signal through the AR.
Methods
The ethical committee for animal experiments at Göte-
borg University approved this study. Mice were kept in the
animal facility at Göteborg University under standard
conditions of temperature and light, and had free access to
fresh water and standard laboratory chow or soy-free food
pellets R70 (Lactamin AB, Stockholm, Sweden).
Mice and treatments
Experiment 1
3-month-old female C57/B16 mice were ovariectomized
under Ketalar® (Pfizer AB, Täby, Sweden) /Domitor®
(Orion Pharma, Espoo, Finland) anaesthesia and left to
rest for two weeks before start of the experiment. Mice
were given daily s.c. injections of the ER-antagonist ICI
DHT and estren increase the androgen phenotype score in submandibular glands independently of estrogen receptorsFigure 6
DHT and estren increase the androgen phenotype score in submandibular glands independently of estrogen 
receptors. Ovariectomized 11-months-old female WT and DERKO mice were given daily s.c. injections of E2 (0.7 µg/day), 
DHT (120 µg/day) or estren (75 µg/day) during four weeks. Control mice received olive oil. E2 treatment did not dramatically 
affect the androgen phenotype of SMG, in either WT or DERKO mice. THE SMG score for androgen phenotype was high for 
both DHT- and estren-treated mice, of both WT and DERKO genotype, when compared to control mice.Page 7 of 12
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or vehicle Miglyol 812 (generous gift from Recip, Årsta,
Sweden). Simultaneously, both the vehicle and the ICI
group were given daily subcutaneous (s.c.) injections of
17β-estradiol-3-benzoate (E2) (Sigma, St Louis, MO,
USA) (0.7 µg/day), 4-estren-3α, 17β-diol (estren) (Ster-
aloids Inc., Newport, RI, USA) (75 µg/day) or control Mig-
lyol 812 oil for 18–21 days. Each group consisted of 6–10
mice.
Experiment 2
Male and female double heterozygous (ERα+/-β+/-) mice
on a mixed C57B1/6J/129 background, were mated
resulting in WT (ERα+/+β+/+), ERKO (ERα-/-β+/+), BERKO
(ERα+/+β-/-) and DERKO (ERα-/-β-/-) offspring[24,25].
Genotyping of tail DNA was performed as previously
described[26,27]. 11-month-old female WT and DERKO
mice were ovariectomized under Ketalar®/Domitor®
anaesthesia. Mice were given daily s.c. injections of E2
(0.7 µg/day), 5α-dihydrotestosterone (DHT) (Sigma)
(120 µg/day) or estren (75 µg/day) during four weeks.
Control mice received vehicle olive oil (Apoteksbolaget,
Sweden). Each group consisted of 6–8 mice.
Experiment 3
9-month-old male WT and DERKO mice were orchidect-
omized under Ketalar®/Domitor® anaesthesia. Mice were
treated for 4 weeks with E2 (0.05 µg/day) or DHT (45 µg/
day), administered by s.c. silastic implants (Silclear Tub-
ing, Degania Silicone, Jordan Valley, Israel) in the cervical
region[18]. Vehicle animals received empty implants.
Each group consisted of 4–8 mice.
Experiment 4
Untreated 18-month-old female WT, ERKO, BERKO, and
DERKO mice were used in the experiment. Each group
consisted of 7–8 mice.
Tissue collection and single-cell preparation
Mice were anaesthetised by Ketalar®/Domitor® , bled and
killed by cervical dislocation. SMG were dissected,
weighed and fixed in paraformaldehyd. Thymi were
DHT reduces thymus cellularity independently of estrogen receptorsFigure 7
DHT reduces thymus cellularity independently of estrogen receptors. 9-month-old male WT and DERKO mice 
were orchidectomized and treated for 4 weeks with E2 (0.05 µg/day) or DHT (45 µg/day), administered by s.c. silastic 
implants. Vehicle animals received empty implants. The E2-mediated reduction of thymus cellularity seen in WT mice, could 
not be detected in DERKO mice. Treatment with DHT resulted in a dramatic reduction of thymus cellularity independently of 
ER genotype. One-way ANOVA followed by Fisher's test was used to compare data from mice in different treatment groups. 
Results are presented as mean ± standard deviation. ***P < 0.001Page 8 of 12
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prepared by mashing the organs through a 70 µm cell-
strainer (BD, Franklin Lakes, NJ, USA). Bone marrow cells
were harvested from femur and tibia by flushing with 2 ml
Phosphate Buffered Saline (PBS). Cells were kept in a 50/
50 mixture of complete medium (Iscoves-medium
enriched with 50 µg/ml Gentamicin (Sigma), 4 mM L-
glutamine (Sigma), 50 µM Mercaptoethanol (Sigma) and
10 % Fetal Calf Serum (FCS) (Biological Ind., Beit Hae-
mek, Israel)) and PBS until use. Thymus and bone mar-
row cells were centifuged at 515 × g for 5 min. Pelleted
bone marrow cells were re-suspended in Tris-buffered
0.83% NH4Cl solution (pH 7.29) for 5 minutes to lyse
erythrocytes. After washing in PBS the total number of
thymus and bone marrow cells was calculated using an
automated cell counter (Sysmex, Kobe, Japan). Cells were
re-suspended in complete medium before use.
Flow cytometry
Bone marrow cells were subjected to Fluorescence Acti-
vated Cell Sorter (FACS) analysis. Cells were stained with
fluorescein isothiocyanate (FITC) labelled antibodies to
CD45R/B220 (clone RA3-6B2, BD PharMingen) and allo-
phycocyanin (APC) conjugated antibodies to CD 19
(clone 1D3, BD PharMingen). Row cytometry was per-
formed on a FACSCalibur and analyzed using Paint-A-
Gate software (BD). The FACS data are presented as
percentage positively stained bone marrow cells of all
nucleated cells.
Histological examination
Histological examination of SMG was performed in a
light microscope (×100) after routine 4% paraformalde-
hyde fixation, dehydration, paraffin embedding and prep-
aration of 4 µm thick tissue sections, followed by staining
with hematoxylin and eosin[28]. The degree of the andro-
gen phenotype in the SMG sections were scored from 0 to
3, where 0 represents no androgen phenotype and 3 is the
highest score for androgen phenotype. Representative pic-
tures for the different scorings (0–3) are presented in fig.
3.
DHT increases the score for androgen phenotype in submandibular glands independently of estrogen receptorsFigure 8
DHT increases the score for androgen phenotype in submandibular glands independently of estrogen recep-
tors. 9-month-old male WT and DERKO mice were orchidectomized and treated for 4 weeks with E2 (0.05 µg/day) or DHT 
(44 µg/day), administered by s.c. silastic implants. Vehicle animals received empty implants. E2-treatment did not affect the 
androgen phenotype of SMG in either WT or DERKO mice. The SMG score for androgen phenotype was increased in DHT 
treated mice of both WT and DERKO genotype.Page 9 of 12
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All values were first tested for normal distribution using
the Shapiro-Wilk test. One-way ANOVA followed by
Fisher's test were then used to compare data from mice in
different treatment groups (experiment 1–3), or from
mice of different genotypes (experiment 4). Results are
presented as mean ± standard deviation. Two-sided testes
were used and P < 0.05 was considered statistically
significant. The programs Prism 4.0 and Statview 5.0.1
were used for statistical calculations.
List of abbreviations
AR: androgen receptor




ERα: estrogen receptor α
ERβ: estrogen receptor β
estren: 4-estren-3α,17β-diol
GCT: granular convoluted tubules
ORX: orchidectomized
Untreated aged female mice lacking ERα display androgen phenotype of submandibular glandsFigure 9
Untreated aged female mice lacking ERα display androgen phenotype of submandibular glands. Untreated 18-
month-old WT, ERKO, BERKO, and DERKO mice were used in the experiment. Aged female mice lacking ERα (ERKO) dis-
played an increased SMG weight (A), size (C) and androgen phenotype (B). One-way ANOVA followed by Fisher's test was 
used to compare data from mice of different genotypes in (A). Results are presented as mean ± standard deviation. *** P < 
0.001Page 10 of 12
(page number not for citation purposes)





UI participated in the planning, termination and execu-
tion of experiments, analysed and interpreted data,
drafted the manuscript.
BH participated in the termination of experiments, ana-
lysed and interpreted the submandibular gland sections,
critically reviewed the manuscript.
MCE participated in the termination and execution of
experiments and analysed interpreted data, critically
reviewed the manuscript.
CJ participated in the termination and execution of exper-
iments, critically reviewed the manuscript.
SMS participated in the planning, termination and execu-
tion of experiments, critically reviewed the manuscript.
ML participated in the planning, termination and execu-
tion of experiments, critically reviewed the manuscript.
JÅG provided the estrogen receptor knock-out mice and
participated in the design of the studies, critically
reviewed the manuscript.
CO conceived of the studies, and participated in their
design and coordination, critically reviewed the
manuscript.
HC conceived of the studies, and participated in their
design, coordination and execution, helped to draft the
manuscript.
Acknowledgements
We thank Berit Eriksson for excellent technical assistance, and Stefan Nils-
son at Karo Bio for providing estren to experiment 2. This study was sup-
ported by grants from the Börje Dahlin foundation, the Göteborg Medical 
Society, The Swedish association against Rheumatism, the King Gustav V's 
80 year's foundation, Reumaforskningsfond Margareta, the Medical Faculty 
of Göteborg University (LUA), the Novo Nordiska foundation, the Swedish 
Medical Research Council, KaroBio AB and the Swedish Cancer Fund.
References
1. Marotti T, Sirotkovic M, Pavelic J, Gabrilovac J, Pavelic K: In vivo
effect of progesteron and estrogen on thymus mass and T-
cell functions in female mice.  Horm Metab Res 1984, 16:201-203.
2. Medina KL, Smithson G, Kincade PW: Suppression of B lym-
phopoiesis during normal pregnancy.  J Exp Med 1993,
178:1507-1515.
3. Medina KL, Kincade PW: Pregnancy-related steroids are poten-
tial negative regulators of B lymphopoiesis.  Proc Natl Acad Sci
USA  1994, 91:5382-5386.
4. Smithson G, Beamer WG, Shultz KL, Christianson SW, Shultz LD,
Kincade PW: Increased B lymphopoiesis in genetically sex
steroid-deficient hypogonadal (hpg) mice.  J Exp Med 1994,
180:717-720.
5. Rijhsinghani AG, Thompson K, Bhatia SK, Waldschmidt TJ: Estrogen
blocks early T cell development in the thymus.  Am J Reprod
Immunol  1996, 36:269-277.
6. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Involution of the mam-
malian thymus, one of the leading regulators of aging.  In Vivo
1997, 11:421-440.
7. Frey-Wettstein M, Craddock CG: Testosterone-induced deple-
tion of thymus and marrow lymphocytes as related to lym-
phopoiesis and hematopoiesis.  Blood 1970, 35:257-271.
8. Viselli SM, Reese KR, Fan J, Kovacs WJ, Olsen NJ: Androgens alter
B cell development in normal male mice.  Cell Immunol 1997,
182:99-104.
9. Benten WP, Becker A, Schmitt-Wrede HP, Wunderlich F: Develop-
mental regulation of intracellular and surface androgen
receptors in T cells.  Steroids 2002, 67:925-931.
10. Chretien M: Action of testosterone on the differentiation and
secretory activity of a target organ: the submaxillary gland
of the mouse.  Int Rev Cytol 1977, 50:333-396.
11. Oda M, Yamamoto R, Terada N, Nishizawa Y, Takatsuka D, Kitamura
Y, Matsumoto K: Maintenance by androgen and thyroid hor-
mone of androgen-induced convoluted tubular cells in
mouse submandibular glands.  Anat Rec 1992, 232:453-457.
12. Gresik EW: The granular convoluted tubule (GCT) cell of
rodent submandibular glands.  Microsc Res Tech 1994, 27:1-24.
13. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G,
Waterfield M, Chambon P: Cloning of the human oestrogen
receptor cDNA.  J Steroid Biochem 1986, 24:77-83.
14. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA:
Cloning of a novel receptor expressed in rat prostate and
ovary.  Proc Natl Acad Sci U S A 1996, 93:5925-5930.
15. Centrella M, McCarthy TL, Chang WZ, Labaree DC, Hochberg RB:
Estren (4-estren-3alpha,17beta-diol) is a prohormone that
regulates both androgenic and estrogenic transcriptional
effects through the androgen receptor.  Mol Endocrinol 2004,
18:1120-1130.
16. Krishnan V, Bullock HA, Yaden B, Liu M, Barr RJ, Montrose-Rafizadeh
C, Chen K, Dodge JA, Bryant HU: The Non-genotropic Synthetic
Ligand Estren (4-estren-3{alpha}17{beta}-diol) is a High
Affinity Genotropic Androgen Receptor Agonist.  Mol
Pharmacol 2004.
17. Islander U, Erlandsson MC, Chavoshi T, Jochems C, Moverare S, Nils-
son S, Ohlsson C, Gustafsson JA, Carlsten H: Estren-mediated
inhibition of T lymphopoiesis is estrogen receptor-independ-
ent whereas its suppression of T cell-mediated inflammation
is estrogen receptor-dependent.  Clin Exp Immunol 2005,
139:210-215.
18. Vandenput L, Boonen S, Van Herck E, Swinnen JV, Bouillon R, Vander-
schueren D: Evidence from the aged orchidectomized male
rat model that 17beta-estradiol is a more effective bone-
sparing and anabolic agent than 5alpha-dihydrotestosterone.
J Bone Miner Res 2002, 17:2080-2086.
19. Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohls-
son C: Estrogen receptor specificity in the regulation of the
skeleton in female mice.  J Endocrinol 2001, 171:229-236.
20. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L,
Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS,
et al.: Nongenotropic, sex-nonspecific signaling through the
estrogen or androgen receptors: dissociation from tran-
scriptional activity.  Cell 2001, 104:719-730.
21. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L,
Fu Q, Mancino AT, Wen Y, et al.: Reversal of bone loss in mice
by nongenotropic signaling of sex steroids.  Science 2002,
298:843-846.
22. Kousteni S, Han L, Chen JR, Almeida M, Plotkin LI, Bellido T, Manol-
agas SC: Kinase-mediated regulation of common transcrip-
tion factors accounts for the bone-protective effects of sex
steroids.  J Clin Invest 2003, 111:1651-1664.
23. Moverare S, Dahllund J, Andersson N, Islander U, Carlsten H, Gus-
tafsson JA, Nilsson S, Ohlsson C: Estren is a selective estrogenPage 11 of 12
(page number not for citation purposes)
BMC Immunology 2005, 6:16 http://www.biomedcentral.com/1471-2172/6/16Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
receptor modulator with transcriptional activity.  Mol
Pharmacol 2003, 64:1428-1433.
24. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar
M, Korach KS, Gustafsson JA, Smithies O: Generation and repro-
ductive phenotypes of mice lacking estrogen receptor beta.
Proc Natl Acad Sci U S A 1998, 95:15677-15682.
25. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O:
Alteration of reproductive function but not prenatal sexual
development after insertional disruption of the mouse estro-
gen receptor gene.  Proc Natl Acad Sci U S A 1993, 90:11162-11166.
26. Vidal O, Lindberg MK, Hollberg K, Baylink DJ, Andersson G, Lubahn
DB, Mohan S, Gustafsson JA, Ohlsson C: Estrogen receptor spe-
cificity in the regulation of skeletal growth and maturation in
male mice.  Proc Natl Acad Sci U S A 2000, 97:5474-5479.
27. Islander U, Erlandsson MC, Hasseus B, Jonsson CA, Ohlsson C, Gus-
tafsson JA, Dahlgren U, Carlsten H: Influence of oestrogen recep-
tor alpha and beta on the immune system in aged female
mice.  Immunology 2003, 110:149-157.
28. Carlsten H, Tarkowski A, Jonsson R, Nilsson LA: Expression of het-
erozygous Ipr gene in MRL mice. II. Acceleration of glomer-
ulonephritis, sialadenitis, and autoantibody production.
Scand J Immunol 1990, 32:21-28.Page 12 of 12
(page number not for citation purposes)
